

Amendments to the Claims: This listing of claims will replace all prior versions, and listings, of claims in the application

Listing of Claims:

Claims 1-20 (canceled).

Claim 21 (Previously Presented): An isolated polynucleotide comprising a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO:4.

Claim 22 (Previously Presented): The isolated polynucleotide of claim 21, wherein the polynucleotide consists of the nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO:4.

Claim 23 (Previously Presented): The isolated polynucleotide of claim 21, wherein the polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO:3.

Claim 24 (Previously Presented): The isolated polynucleotide of claim 23, wherein the polynucleotide consists of the nucleotide sequence set forth in SEQ ID NO:3.

Claim 25 (Previously Presented): An isolated TR7 polynucleotide comprising a nucleotide sequence that encodes at least 20 contiguous amino acids of the amino acid sequence set forth in SEQ ID NO:4.

Claim 26 (Previously Presented): The isolated TR7 polynucleotide of claim 25 wherein the nucleotide sequence encodes at least one cysteine-rich motif characteristic of an extracellular domain of Tumor Necrosis Factor Receptors.

Claim 27 (Previously Presented): The isolated TR7 polynucleotide of claim 25 wherein the nucleotide sequence encodes at least one Cys-x-x-Cys amino acid motif.

Claim 28 (Previously Presented): The isolated TR7 polynucleotide of claim 25 wherein the at least 20 contiguous amino acids of the amino acid sequence of SEQ ID NO:4 are also present in SEQ ID NO:2.

Claim 29 (Previously Presented): The isolated TR7 polynucleotide of claim 25 wherein the at least 20 contiguous amino acids of the amino acid sequence of SEQ ID NO:4 are also present in SEQ ID NO:6.

Claim 30 (Previously Presented): An isolated polynucleotide comprising a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO:6.

Claim 31 (Previously Presented): The isolated polynucleotide of claim 30, wherein the polynucleotide consists of the nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO:6.

Claim 32 (Previously Presented): The isolated polynucleotide of claim 30, wherein the polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO:5.

Claim 33 (Previously Presented): The isolated polynucleotide of claim 32, wherein the polynucleotide consists of the nucleotide sequence set forth in SEQ ID NO:5.

Claim 34 (Previously Presented): An isolated TR7 polynucleotide comprising a nucleotide sequence that encodes at least 20 contiguous amino acids of the amino acid sequence set forth in SEQ ID NO:6.

Claim 35 (Previously Presented): The isolated TR7 polynucleotide of claim 34 wherein the nucleotide sequence encodes at least one cysteine-rich motif characteristic of an extracellular domain of Tumor Necrosis Factor Receptors.

Claim 36 (Previously Presented): The isolated TR7 polynucleotide of claim 34 wherein the nucleotide sequence encodes at least one Cys-x-x-Cys amino acid motif.

Claim 37 (Previously Presented): The isolated TR7 polynucleotide of claim 34 wherein the at least 20 contiguous amino acids of the amino acid sequence of SEQ ID NO:6 are also present in SEQ ID NO:2.